SEGMENT INFORMATION (Tables)

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Schedule of Net Loss of Significant Expense

The following table presents segment revenue and significant expenses regularly reviewed by the CODM for the years ended December 31, 2024 and 2023 (in thousands):

	Year ended December 31,
	2024		2023
Royalty revenues	$	501	$	424
Operating expenses
Research and development:
Repibresib (VYN201)	16,271		4,593
VYN202	11,262		8,770
Other segment items*	3,413		2,944
General and administrative	13,192		13,375
Total operating expenses	44,138		29,682
Operating loss	(43,637)		(29,258)
Other income, net	3,834		1,386
Loss from continuing operations before income taxes	(39,803)		(27,872)
Income tax expense	4		—
Loss from continuing operations	(39,807)		(27,872)
Loss from discontinued operations, net of income taxes	(27)		(580)
Net loss	$	(39,834)	$	(28,452)

*Other segment items relate to research and development expenses that cannot be directly allocated to one specific product candidate, such as employee-related expenses, consulting, quality control, regulatory, and general IP legal expenses.